One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Middle East
Sample Provided: no
Payment Terms: T/T
Indications:
Improvement of glycemic control in adults with type 2 diabetes mellitus.
Treatment of adults with obesity or overweight, having weight-related comorbidities or complications.
Mechanism of Action: Liraglutide mimics the action of the endogenous hormone GLP-1, which enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, delays gastric emptying, and reduces appetite and food intake.
Pharmacokinetics:
Absorption: Subcutaneously administered, with peak plasma concentrations achieved in 11 hours.
Distribution: Vd approximates 20-25 L.
Metabolism: Metabolized via endogenous pathways similarly to large proteins without a specific organ as a major route of elimination.
Excretion: Mainly through feces.
Form: Liraglutide API is typically found as a clear and colorless solution or as a white lyophilized powder.